Methods: Data were obtained from published Genome-Wide Association study (GWAS) databases. A two-sample Mendelian randomization (MR) analysis was performed with genetic variants associated with risk ...
The median interval from cancer diagnosis to randomization was 11.7 months (4.0-26.4). The ponsegromab 400-mg group had the highest proportion of patients with stage IV disease (86% vs 65-74% in the ...
Limitations of the study include the low sample sizes, and the exploratory, post hoc nature of the study which did not allow for statistical testing, randomization, or a control group. “This work ...